menu
    • menu
    [{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"ImmPACT Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"CAR T-cell Therapy","moa":"CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImmPACT Bio \/ ImmPACT Bio","highestDevelopmentStatusID":"1","companyTruncated":"ImmPACT Bio \/ ImmPACT Bio"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"venBio Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"CD19-CD20 bi-specific CAR-T Cell Therapy","moa":"CD19\/CD20","graph1":"Oncology","graph2":"Phase I","graph3":"ImmPACT Bio","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"ImmPACT Bio \/ venBio Partners","highestDevelopmentStatusID":"6","companyTruncated":"ImmPACT Bio \/ venBio Partners"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"IMPT-314","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImmPACT Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Not Applicable"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"IMPT-314","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmPACT Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Not Applicable"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"IMPT-514","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"ImmPACT Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmPACT Bio \/ Not Applicable"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"IMPT-314","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"ImmPACT Bio \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Lyell Immunopharma"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"IMPT-314","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"ImmPACT Bio \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Lyell Immunopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by ImmPACT Bio

    Menu

    ImmPACT Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Lyell Immunopharma

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lyell Immunopharma Completes Acquisition of ImmPACT Bio

                            Details : Lyell will acquire worldwide rights to ImmPACT’s pipeline, the next- gen CD19/CD20 autologous CAR T-cell therapy, which includes IMPT-314, it is currently in clinical development for B-cell lymphoma.

                            Brand Name : IMPT-314

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $30.0 million

                            October 31, 2024

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Lyell Immunopharma

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Lyell Immunopharma

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lyell Immunopharma Acquires ImmPACT Bio, Refocuses on CAR T-cell Therapy

                            Details : Lyell will acquire worldwide rights to ImmPACT’s pipeline, the next- gen CD19/CD20 autologous CAR T-cell therapy, which includes IMPT-314, it is currently in clinical development for B-cell lymphoma.

                            Brand Name : IMPT-314

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $30.0 million

                            October 24, 2024

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Lyell Immunopharma

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMPT-514

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ImmPACT Bio Wins FDA Clearance for CD19/CD20 CAR-T Therapy in Multiple Sclerosis

                            Details : IMPT-514 is a CD19/CD20-targeting chimeric antigen receptor (CAR) T-cell therapy that utilizes a potent bispecific CAR and a 4-1BB, which is under development for Multiple Sclerosis.

                            Brand Name : IMPT-514

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 21, 2024

                            Lead Product(s) : IMPT-514

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ImmPACT Bio Granted FDA Fast Track Designation for IMPT-314 in Patients with Relapsed or Refractory Aggressive...

                            Details : IMPT-314 is a bispecific autologous CAR T-cell therapy targeting the B-cell antigens CD19 and CD20. It was granted FDA fast track designation and will be studied in patients with aggressive B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL)...

                            Brand Name : IMPT-314

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 15, 2023

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma

                            Details : IMPT-314, a bispecific “OR-Gate” autologous CAR T-cell therapy targeting the B-cell antigens CD19 and CD20. IMPT-314 will be studied in a Phase 1/2 clinical trial in patients with aggressive B-cell lymphoma, including diffuse large B-cell lymphoma (D...

                            Brand Name : IMPT-314

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 24, 2023

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD19-CD20 bi-specific CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : venBio Partners

                            Deal Size : $111.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updat...

                            Details : In addition, ImmPACT Bio provided an update to the Phase 1 clinical study evaluating its CD19-CD20 bi-specific CAR T in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (R/R B-cell NHL) at University of California, Los Angeles (UCLA).

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 20, 2022

                            Lead Product(s) : CD19-CD20 bi-specific CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : venBio Partners

                            Deal Size : $111.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ImmPACT Bio

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR T-cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Kalthera

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            ImmPACT Merger with Kalthera to Progress Next-Generation CAR Therapies Treatment

                            Details : Kalthera is currently progressing a clinical trial at the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center with a pioneering bispecific chimeric antigen receptor (CAR) T-cell immunotherapy candidate targeting CD19/CD20.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 22, 2021

                            Lead Product(s) : CAR T-cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Kalthera

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth